The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma

Shuang Ye; Shuai Liu; Shuling Zhou; Libing Xiang; Xiaohua Wu; Huijuan Yang

doi:10.3233/cbm-190904

journal article Open Access Feb 18, 2020

The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma

Shuang Ye Shuai Liu

Shuling Zhou Libing Xiang Xiaohua Wu

Huijuan Yang

Cancer Biomarkers Vol. 27 No. 2 pp. 189-194 · SAGE Publications

View at Publisher Save 10.3233/cbm-190904

Topics

No keywords indexed for this article. Browse by subject →

References

26

[1]

Anglesio "Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010" Gynecologic Oncology (2011) 10.1016/j.ygyno.2011.01.005

[2]

del Carmen "Clear cell carcinoma of the ovary: A review of the literature" Gynecologic Oncology (2012) 10.1016/j.ygyno.2012.04.021

[3]

Ye "Comparison of clinical characteristic and prognosis between ovarian clear cell carcinoma and serous carcinoma: A 10-year cohort study of chinese patients" PloS One (2015) 10.1371/journal.pone.0133498

[4]

Itamochi "Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma" Cancer Science (2008) 10.1111/j.1349-7006.2008.00747.x

[5]

Yamaguchi "Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes" Oncogene (2010) 10.1038/onc.2009.470

[6]

Okamoto "Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma" Molecular Carcinogenesis (2015) 10.1002/mc.22072

[7]

S.I. Kim, J.W. Lee, M. Lee, H.S. Kim, H.H. Chung, J.W. Kim, N.H. Park, Y.S. Song and J.S. Seo, Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing, Gynecologic Oncology (2017). 10.1016/j.ygyno.2017.12.005

[8]

Murakami "Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks" The American Journal of Pathology (2017) 10.1016/j.ajpath.2017.06.012

[9]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[10]

Amit "PET/CT in gynecologic cancer: present applications and future prospects – a clinician’s perspective" Obstetrics and Gynecology Clinics of North America (2011) 10.1016/j.ogc.2011.02.001

[11]

Chung "Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer" Annals of Surgical Oncology (2012) 10.1245/s10434-011-2153-x

[12]

Liao "Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer" Clinical Nuclear Medicine (2013) 10.1097/rlu.0b013e31829f57fa

[13]

Konishi "Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma" International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society (2014) 10.1097/igc.0000000000000180

[14]

Lee "The role of metabolic tumor volume and total lesion glycolysis on (1)(8)F-FDG PET/CT in the prognosis of epithelial ovarian cancer" European Journal of Nuclear Medicine and Molecular Imaging (2014) 10.1007/s00259-014-2803-x

[15]

Kim "Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer" Gynecologic Oncology (2015) 10.1016/j.ygyno.2014.12.032

[16]

Vargas "Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery" European Radiology (2015) 10.1007/s00330-015-3729-9

[17]

Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum‐based adjuvant chemotherapy

Makoto Yamamoto, Tetsuya Tsujikawa, Yuko Fujita et al.

Cancer Science 2016 10.1111/cas.12890

[18]

Gallicchio "F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer" European Journal of Radiology (2017) 10.1016/j.ejrad.2017.05.036

[19]

S. Liu, Z. Feng, Z. Jiang, H. Wen, J. Xu, H. Pan, Y. Deng, L. Zhang, X. Ju, X. Chen and X. Wu, Prognostic predictive value of preoperative intratumoral 2-deoxy-2-(18F)fluoro-D-glucose uptake heterogeneity in patients with high-grade serous ovarian cancer, Nuclear Medicine Communications (2018). 10.1097/mnm.0000000000000861

[20]

S. Liu, Z. Feng, H. Wen, Z. Jiang, H. Pan, Y. Deng, L. Zhang, X. Ju, X. Chen and X. Wu, (18)F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value, Japanese Journal of Radiology (2018). 10.1007/s11604-018-0755-y

[21]

Liu "Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma" Gynecologic Oncology (2012) 10.1016/j.ygyno.2012.03.021

[22]

FIGO staging for carcinoma of the vulva, cervix, and corpus uteri, International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics 125 (2014), 97–8. 10.1016/j.ijgo.2014.02.003

[23]

Ye "(18)F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications" BMC Cancer (2019) 10.1186/s12885-019-5441-7

[24]

Zhu "Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma" Journal of Gynecologic Oncology (2017) 10.3802/jgo.2017.28.e77

[25]

Tanizaki "Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer" International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society (2014) 10.1097/igc.0000000000000074

[26]

Yu "GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer" Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology (2009) 10.1016/j.radonc.2009.07.003

Metrics

7

Citations

26

References

Details

Published: Feb 18, 2020
Vol/Issue: 27(2)
Pages: 189-194
License: View

Authors

S

Shuang Ye

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

S

Shuai Liu

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

S

Shuling Zhou

Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

L

Libing Xiang

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

X

Xiaohua Wu

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

H

Huijuan Yang

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Cite This Article

Shuang Ye, Shuai Liu, Shuling Zhou, et al. (2020). The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma. Cancer Biomarkers, 27(2), 189-194. https://doi.org/10.3233/cbm-190904

The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma

You May Also Like